BioSpace News Archive

CorMedix Inc. today announced the appointment of Robert A. Stewart to the CorMedix Board of Directors.

Standard BioTools Inc. today announced the launch of its newest imaging technology, the Hyperion XTi™ Imaging System, during the American Association for Cancer Research (AACR) meeting in Orlando.

In support of global initiatives to advance molecular profiling in oncology, Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant and the opening of its submissions for Spring 2023.

Senti Biosciences, Inc. today announced the presentation of preclinical data from multiple wholly-owned pipeline programs at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-19, 2023, in Orlando, Florida.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) today announces the initiation of an open-label Phase II trial evaluating eftilagimod alpha (efti), a soluble LAG-3 protein and MHC Class II agonist, in combination with pembrolizumab and radiotherapy in up to 40 soft tissue sarcoma (STS) patients in the neoadjuvant (prior to surgery) setting.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. announced a master distributor agreement with AD Ports Logistics, a subsidiary of the Logistics Cluster, AD Ports Group, a leading global facilitator of trade, logistics and industry based in Abu Dhabi.

Tempest Therapeutics, Inc. announced that new data from its TPST-1120 and TREX1 programs were highlighted in two poster presentations at the 2023 American Association for Cancer Research Annual Meeting taking place April 14-19, 2023 in Orlando, FL.

Precision Optics Corporation, Inc. announced the appointment of medical device and aerospace/defense industry manufacturing veteran, Mahesh Lawande, as the Company’s Chief Operating Officer effective April 24, 2023.

Trefoil Therapeutics today announced multiple presentations providing evidence for clinical and preclinical efficacy of the company’s investigational medicine TTHX1114 for improving visual outcomes and protection against corneal endothelial damage at the Annual Association for Research in Vision and Ophthalmology (ARVO) Meeting in New Orleans, April 23-27, 2023.

GlucoTrack, Inc. announced the closing of a firm commitment underwritten public offering of shares of its common stock with gross proceeds to the Company expected to be approximately $10.0 million, before deducting underwriting discounts and other estimated expenses payable by the Company.